Tracers / [89Zr]Zr-Df-pertuzumab-800CW
[89Zr]Zr-Df-pertuzumab-800CW
Also written as Df-pertuzumab-800CW; Zr-89 Df-pertuzumab-800CW; Zr-89-Df-pertuzumab-800CW
- Radionuclide
- Zr-89 t½ 4704 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- Anti-HER2 monoclonal antibody (pertuzumab) dual-labeled with DFO chelator and IRDye 800CW
- Target / mechanism
- HER2 (human epidermal growth factor receptor 2) PMID 31392081
- Clinical application
- Dual-modality PET/near-infrared fluorescence imaging for preoperative imaging and image-guided tumor resection in HER2-expressing ovarian cancer models PMID 31392081
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 31392081 2019 Am J Cancer Res |
Need this precursor?We can point you to suppliers for [89Zr]Zr-Df-pertuzumab-800CW, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [89Zr]Zr-Df-pertuzumab-800CW.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with Zr-89. | Stage 28: added indication(s) oth-radioguided-surgery from consolidated missing-rubric review.